|Other Names||Sideroflexin-5, SFXN5|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6403a was selected from the N-term region of human SFXN5. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Transports citrate. Potential iron transporter (By similarity).|
|Cellular Location||Mitochondrion membrane; Multi- pass membrane protein|
|Tissue Location||Primarily expressed in the brain.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Parkinson's disease (PD) is a multifactorial disease that appears to arise from the effects of both genetic and environmental influences. The known genetic factors include multiple genes that have been identified in related parkinsonian syndromes, as well as alpha-synuclein. Genes associated with either PD or Parkinson-related disorders include parkin, DJ-1, ubiquitin C-terminal hydrolase isozyme L1 (UCH-L1), nuclear receptor-related factor 1 (NURR1), and alpha-synuclein. SFXN5 has been known to locate at the Park3 region of chromosome 2p (PARK3; OMIM 602404). However, sequence analysis of 2p13 linked individuals affected with PD did not reveal any potentially pathogenic mutations within SFXN5, suggesting SFXN5 may not correspond to PARK3 (Lockhart et al.). Search for Park3 gene is still under development and HtrA2 is suspected to be one candidate.
Lockhart,P.J., et al. Gene 285 (1-2), 229-237 (2002)Snyder H and Wolozin B. J Mol Neurosci. 24(3):425-42. Review. (2004)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.